Alkermes (NASDAQ:ALKS) Shares Purchased Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Alkermes plc (NASDAQ:ALKS). In a filing disclosed on September 04th, the Representative disclosed that they had bought between $15,001 and $50,000 in Alkermes stock on July 30th.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Mesabi Trust (NYSE:MSB) on 7/31/2026.
• Purchased $1,001 – $15,000 in shares of Praxis Precision Medicines (NASDAQ:PRAX) on 7/30/2026.
• Sold $15,001 – $50,000 in shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) on 7/30/2026.
• Sold $100,001 – $250,000 in shares of Alibaba Group (NYSE:BABA) on 7/24/2026.
• Sold $1,001 – $15,000 in shares of Adobe (NASDAQ:ADBE) on 7/24/2026.
• Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 7/21/2026.
• Purchased $1,001 – $15,000 in shares of SailPoint (NASDAQ:SAIL) on 7/21/2026.
• Purchased $1,001 – $15,000 in shares of Glacier Bancorp (NYSE:GBCI) on 7/21/2026.
• Sold $1,001 – $15,000 in shares of FedEx (NYSE:FDX) on 7/21/2026.
• Purchased $1,001 – $15,000 in shares of Marvell Technology (NASDAQ:MRVL) on 7/17/2026.

Alkermes Stock Performance

Shares of ALKS stock opened at $46.10 on Tuesday. The firm has a 50 day moving average of $50.43 and a two-hundred day moving average of $41.04. The stock has a market capitalization of $7.73 billion, a PE ratio of 121.32 and a beta of 0.31. The company has a quick ratio of 1.85, a current ratio of 2.30 and a debt-to-equity ratio of 0.82. Alkermes plc has a 52 week low of $25.17 and a 52 week high of $55.67.

Insiders Place Their Bets

In other news, Director Nancy Lynn Md Snyderman sold 44,472 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $50.35, for a total transaction of $2,239,165.20. Following the transaction, the director directly owned 15,395 shares in the company, valued at approximately $775,138.25. This trade represents a 74.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Christopher Wright sold 2,000 shares of the company’s stock in a transaction on Friday, June 12th. The shares were sold at an average price of $45.10, for a total transaction of $90,200.00. Following the completion of the sale, the director owned 25,680 shares of the company’s stock, valued at approximately $1,158,168. This trade represents a 7.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 87,150 shares of company stock valued at $4,332,413. 4.59% of the stock is owned by insiders.

Hedge Funds Weigh In On Alkermes

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. California State Teachers Retirement System increased its position in shares of Alkermes by 5,527.7% during the second quarter. California State Teachers Retirement System now owns 10,343,402 shares of the company’s stock worth $541,994,000 after purchasing an additional 10,159,607 shares in the last quarter. Norges Bank acquired a new stake in shares of Alkermes in the 4th quarter valued at about $54,442,000. Baker BROS. Advisors LP grew its stake in Alkermes by 23.7% during the 4th quarter. Baker BROS. Advisors LP now owns 10,012,267 shares of the company’s stock worth $280,143,000 after buying an additional 1,920,916 shares during the last quarter. First Trust Advisors LP increased its position in Alkermes by 104.2% during the first quarter. First Trust Advisors LP now owns 2,968,785 shares of the company’s stock worth $104,976,000 after buying an additional 1,514,783 shares during the period. Finally, JPMorgan Chase & Co. lifted its stake in Alkermes by 32.0% in the fourth quarter. JPMorgan Chase & Co. now owns 5,184,547 shares of the company’s stock valued at $145,064,000 after buying an additional 1,256,377 shares during the last quarter. 95.21% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Stifel Nicolaus reaffirmed a “buy” rating and issued a $63.00 price target (up from $45.00) on shares of Alkermes in a research report on Monday, July 20th. Royal Bank Of Canada boosted their price objective on Alkermes from $45.00 to $56.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 9th. TD Cowen raised their target price on shares of Alkermes from $42.00 to $50.00 and gave the company a “buy” rating in a report on Monday, June 22nd. Weiss Ratings reiterated a “hold (c)” rating on shares of Alkermes in a report on Friday, August 7th. Finally, Needham & Company LLC lifted their price objective on shares of Alkermes from $61.00 to $62.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $54.56.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.